Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-08-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: radiationor equalequal tosurgerydisease
  Phrases that lowered it: oncology19diagnosedupperwomen
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 52.3% (raises risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Maximum age: 99 (lowers risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.9% (raises risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 3537 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• ATOM_local Ablative Therapy NCT01941654 · started 2013 · scored riskier than 78% of active trials completed
• Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC NCT02064491 · started 2014 · scored riskier than 94% of active trials completed
• A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR NCT02178397 · started 2014 · scored riskier than 89% of active trials terminated
• Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC NCT00997334 · started 2010 · scored riskier than 99% of active trials completed
• BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) NCT01562028 · started 2012 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.